Renal and cardiovascular risk predictive value of two different microalbuminuria screening methods in patients with hypertension with/without diabetes in Portugal

被引:4
作者
Polonia, J. [1 ]
Carvalho, D. [2 ]
Nazare, J. [3 ]
Martins, L. [4 ]
da Silva, P. M. [5 ]
Aguiar, C. [6 ]
Manso, M. C. [7 ]
Carqueja, T. [8 ]
机构
[1] Univ Porto, Hosp Pedro Hispano, Fac Med, CINTESIS,Dept Med, Al Prof Hernani Monteiro, P-4200319 Oporto, Portugal
[2] Univ Porto, Inst Invest & Inovacao Saude, Fac Med, Dept Endocrinol Diabet & Metab,Ctr Hosp S Jaoo, Oporto, Portugal
[3] CHLO Hosp Egas Moniz, Dept Cardiol, Lisbon, Portugal
[4] Hosp Santa Maria da Feira, Dept Cardiol, Santa Maria Feira, Portugal
[5] Hosp Santa Marta, Arterial Invest Unit, Dept Internal Med, Lisbon, Portugal
[6] Hosp Santa Cruz, Dept Cardiol, Carnaxide, Portugal
[7] Univ Porto, Univ Fernando Pessoa, CIAGEB UFP, Fac Hlth Sci,REQUIMTE, Oporto, Portugal
[8] Novartis Farma, Med Dept, Porto Salvo, Portugal
关键词
PRIMARY-CARE; MICRAL-TEST; TEST STRIP; ALBUMINURIA; DISEASE; KIDNEY; TYPE-2;
D O I
10.1038/jhh.2015.120
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
MicRoAlbuminuria sCreening survEy (RACE) was a multicentre, observational, cross-sectional study conducted in primary health-care settings of Portugal. Here, we present a post-hoc analysis from the RACE study, assessing the renal and cardiovascular (CV) risk predictive value of two different microalbuminuria (MA) screening methods, nephelometry with 24-h urine (MA-24 h) and Micral test with occasional urine (MicralA) in patients with hypertension (HTN) with/without type 2 diabetes mellitus (T2DM). Out of 3065 patients, 1173 (38.3%) were in the HTN group without T2DM (HTN) and 1892 (61.7%) in the HTN group with T2DM (HTN+T2DM). The overall prevalence of MA was 50.6% determined by MicralA and 22.1% with MA-24 h. Urinary albumin excretion data obtained by both techniques correlated significantly (r(s) = 0.586; P < 0.001). In all subjects, MicralA showed a sensitivity of 93%, specificity of 62% for detection of MA, with a positive predictive value of 41% and negative predictive value of 97%. With both methods, the presence of MA was independently associated with a higher risk (1.5- to 2.9-fold) of CV and renal organ damage in both HTN and HTN+T2DM groups. MicralA, due to its high sensitivity and negative predictive value, can be considered as a valid and reliable method for MA screening in patients with HTN with/without T2DM.
引用
收藏
页码:726 / 730
页数:5
相关论文
共 28 条
[1]   Standards of Medical Care in Diabetes-2014 [J].
不详 .
DIABETES CARE, 2014, 37 :S14-S80
[2]  
[Anonymous], INT J APPL BASIC MED
[3]  
[Anonymous], 2013, PORT J NEPHROL HYPER, V27, P9
[4]  
[Anonymous], 2013, Education at a Glance 2013: OECD Indicators
[5]   Microalbuminuria in Type 2 Diabetes and Hypertension A marker, treatment target, or innocent bystander? [J].
Basi, Seema ;
Fesler, Pierre ;
Mimran, Albert ;
Lewis, Julia B. .
DIABETES CARE, 2008, 31 :S194-S201
[6]  
Busby Douglas E, 2004, J Clin Hypertens (Greenwich), V6, P8, DOI 10.1111/j.1524-6175.2004.04237.x
[7]  
Cortés-Sanabria L, 2006, REV INVEST CLIN, V58, P190
[8]   Prevalence of microalbuminuria in hypertensive patients with or without type 2 diabetes in a Portuguese primary care setting: The RACE (micRoAlbumin sCreening survEy) study [J].
da Silva, Pedro Marques ;
Carvalho, Davide ;
Nazare, Jose ;
Martins, Luis ;
Aguiar, Carlos ;
Manso, Maria Conceicao ;
Carqueja, Teresa ;
Polonia, Jorge .
REVISTA PORTUGUESA DE CARDIOLOGIA, 2015, 34 (04) :237-246
[9]   Screening, monitoring, and treatment of albuminuria: Public health perspectives [J].
de Jong, Paul E. ;
Curhan, Gary C. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (08) :2120-2126
[10]  
Enache A, 2007, TIMISOARA MED J, V4, P235